Paola Sarchielli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6030414/publications.pdf

Version: 2024-02-01

111 papers 4,659 citations

94433 37 h-index 110387 64 g-index

117 all docs

117 docs citations

117 times ranked 5525 citing authors

#	Article	lF	CITATIONS
1	Proinflammatory Cytokines, Adhesion Molecules, and Lymphocyte Integrin Expression in the Internal Jugular Blood of Migraine Patients Without Aura Assessed Ictally. Headache, 2006, 46, 200-207.	3.9	245
2	Noninvasive vagus nerve stimulation as acute therapy for migraine. Neurology, 2018, 91, e364-e373.	1.1	186
3	Excitatory Amino Acids and Multiple Sclerosis. Archives of Neurology, 2003, 60, 1082.	4.5	174
4	Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders. Trends in Pharmacological Sciences, 2008, 29, 402-412.	8.7	172
5	Effects of central and peripheral inflammation on hippocampal synaptic plasticity. Neurobiology of Disease, 2013, 52, 229-236.	4.4	155
6	Plasma cytokine levels in patients with obstructive sleep apnea syndrome: a preliminary study. Journal of Sleep Research, 2003, 12, 305-311.	3.2	153
7	Increased Levels of Neurotrophins Are Not Specific for Chronic Migraine: Evidence From Primary Fibromyalgia Syndrome. Journal of Pain, 2007, 8, 737-745.	1.4	132
8	Italian guidelines for primary headaches: 2012 revised version. Journal of Headache and Pain, 2012, 13, 31-70.	6.0	129
9	Brain-derived neurotrophic factor in patients with multiple sclerosis. Journal of Neuroimmunology, 2002, 132, 180-188.	2.3	119
10	Current and emerging evidence-based treatment options in chronic migraine: a narrative review. Journal of Headache and Pain, 2019, 20, 92.	6.0	116
11	Endocannabinoids in Chronic Migraine: CSF Findings Suggest a System Failure. Neuropsychopharmacology, 2007, 32, 1384-1390.	5.4	115
12	Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 18985-18990.	7.1	113
13	A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. Alzheimer's Research and Therapy, 2018, 10, 8.	6.2	111
14	Cortical spreading depression as a target for anti-migraine agents. Journal of Headache and Pain, 2013, 14, 62.	6.0	110
15	Pathophysiological basis of migraine prophylaxis. Progress in Neurobiology, 2009, 89, 176-192.	5.7	100
16	Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms. Trends in Pharmacological Sciences, 2007, 28, 188-195.	8.7	96
17	Sensitization, glutamate, and the link between migraine and fibromyalgia. Current Pain and Headache Reports, 2007, 11, 343-351.	2.9	95
18	Applicability of the 1988 IHS Criteria to Headache Patients Under the Age of 18 Years Attending 21 Italian Headache Clinics. Headache, 1995, 35, 146-153.	3.9	94

#	Article	IF	Citations
19	Functional 1H-MRS findings in migraine patients with and without aura assessed interictally. Neurolmage, 2005, 24, 1025-1031.	4.2	84
20	Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels. European Journal of Clinical Pharmacology, 2008, 64, 1-8.	1.9	77
21	Serum and Salivary Magnesium Levels in Migraine and Tension-Type Headache. Results in a Group of Adult Patients. Cephalalgia, 1992, 12, 21-27.	3.9	76
22	Persistent activation of microglia and NADPH oxidase drive hippocampal dysfunction in experimental multiple sclerosis. Scientific Reports, 2016, 6, 20926.	3.3	68
23	Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial. Journal of Headache and Pain, 2012, 13, 677-684.	6.0	67
24	Pathophysiological Bases of Comorbidity in Migraine. Frontiers in Human Neuroscience, 2021, 15, 640574.	2.0	57
25	Obsessiveâ€Compulsive Disorder and Migraine With Medicationâ€Overuse Headache. Headache, 2009, 49, 1005-1013.	3.9	56
26	Sodium valproate in migraine without aura and medication overuse headache: A randomized controlled trial. European Neuropsychopharmacology, 2014, 24, 1289-1297.	0.7	55
27	Serum and Salivary Magnesium Levels in Migraine. Results in a Group of Juvenile Patients. Headache, 1992, 32, 132-135.	3.9	53
28	Fibroblast growth factor-2 levels are elevated in the cerebrospinal fluid of multiple sclerosis patients. Neuroscience Letters, 2008, 435, 223-228.	2.1	52
29	Cytokine secretion and nitric oxide production by mononuclear cells of patients with multiple sclerosis. Journal of Neuroimmunology, 1997, 80, 76-86.	2.3	51
30	Chemokine Levels in the Jugular Venous Blood of Migraine Without Aura Patients During Attacks. Headache, 2004, 44, 961-968.	3.9	48
31	l-Arginine/nitric oxide pathway in chronic tension-type headache: relation with serotonin content and secretion and glutamate content. Journal of the Neurological Sciences, 2002, 198, 9-15.	0.6	45
32	Evidence of hydrogen sulfide involvement in amyotrophic lateral sclerosis. Annals of Neurology, 2015, 77, 697-709.	5.3	45
33	No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. Journal of Neurology, 2018, 265, 2851-2860.	3.6	43
34	Radioligand binding assay of M1–M5 muscarinic cholinergic receptor subtypes in human peripheral blood lymphocytes. Journal of Neuroimmunology, 1999, 99, 224-229.	2.3	41
35	Expression of ionotropic glutamate receptor GLUR3 and effects of glutamate on MBP- and MOG-specific lymphocyte activation and chemotactic migration in multiple sclerosis patients. Journal of Neuroimmunology, 2007, 188, 146-158.	2.3	41
36	Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis. Journal of Neurology, 2019, 266, 2157-2163.	3.6	41

#	Article	IF	Citations
37	Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis. Cell Reports, 2021, 37, 110094.	6.4	38
38	Magnesium Content of Mononuclear Blood Cells in Migraine Patients. Headache, 1994, 34, 160-165.	3.9	36
39	Red Blood Cell Magnesium Levels in Migraine Patients. Cephalalgia, 1993, 13, 94-98.	3.9	35
40	Outcome of Juvenile Headache in Outpatients Attending 23 Italian Headache Clinics*. Headache, 1999, 39, 737-746.	3.9	35
41	Tolerability and efficacy of a combination of paracetamol and caffeine in the treatment of tension-type headache: a randomised, double-blind, double-dummy, cross-over study versus placebo and naproxen sodium. Journal of Headache and Pain, 2008, 9, 367-373.	6.0	35
42	2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes. Journal of Neurology, 2018, 265, 2684-2687.	3.6	35
43	Consistent effects of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: additional findings from the randomized, sham-controlled, double-blind PRESTO trial. Journal of Headache and Pain, 2018, 19, 101.	6.0	34
44	Study of Pressure Pain and Cellular Concentration of Neurotransmitters Related to Nociception in Episodic Tension-Type Headache Patients. Headache, 1997, 37, 565-571.	3.9	33
45			

#	Article	IF	CITATIONS
55	Prevalence of essential tremor in the territory of Lake Trasimeno, Italy: Results of a populationâ€based study. Movement Disorders, 2007, 22, 540-545.	3.9	26
56	Occipital arteriovenous malformations and migraine. Cephalalgia, 2011, 31, 1320-1324.	3.9	25
57	Practical Considerations for the Treatment of Elderly Patients with Migraine. Drugs and Aging, 2006, 23, 461-489.	2.7	22
58	Nutritional Status and Immune Responses. Clinics in Laboratory Medicine, 1993, 13, 455-461.	1.4	21
59	Nerve growth factor and chronic daily headache: a potential implication for therapy. Expert Review of Neurotherapeutics, 2004, 4, 115-127.	2.8	21
60	Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 35, 228-232.	2.0	20
61	Long-Term Risk of Stroke After Transient Global Amnesia in Two Prospective Cohorts. Stroke, 2019, 50, 2555-2557.	2.0	20
62	Immunological Profile of Silent Brain Infarction and Lacunar Stroke. PLoS ONE, 2013, 8, e68428.	2.5	20
63	Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms. Journal of Neuroinflammation, 2021, 18, 259.	7.2	20
64	Stopping Onabotulinum Treatment after the First Two Cycles Might Not Be Justified: Results of a Real-life Monocentric Prospective Study in Chronic Migraine. Frontiers in Neurology, 2017, 8, 655.	2.4	19
65	Antiepileptic drugs in migraine and epilepsy: Who is at increased risk of adverse events?. Cephalalgia, 2018, 38, 274-282.	3.9	19
66	Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: a post hoc analysis of the randomized, sham-controlled, double-blind PRESTO trial. Journal of Headache and Pain, 2018, 19, 98.	6.0	18
67	Immunological findings in patients with migraine and other primary headaches: a narrative review. Clinical and Experimental Immunology, 2022, 207, $11\text{-}26$.	2.6	18
68	Event-Related Potentials in Posttraumatic Headache. Headache, 2001, 41, 579-585.	3.9	17
69	Brain-derived neurotrophic factor in cerebrospinal fluid of patients with chronic daily headache: relationship with nerve growth factor and glutamate levels. Journal of Headache and Pain, 2002, 3, 129-135.	6.0	17
70	Activity levels of a \hat{l}^2 1,6 N-acetylglucosaminyltransferase in lymphomonocytes from multiple sclerosis patients. Journal of the Neurological Sciences, 1997, 151, 177-183.	0.6	16
71	Migraine preventive drug-induced weight gain may be mediated by effects on hypothalamic peptides: The results of a pilot study. Cephalalgia, 2011, 31, 543-549.	3.9	16
72	Genes and primary headaches: discovering new potential therapeutic targets. Journal of Headache and Pain, 2013, 14, 61.	6.0	16

#	Article	IF	CITATIONS
73	Headache associated with acute ischemic stroke. Journal of Headache and Pain, 2001, 2, 25-29.	6.0	14
74	Application of the 1988 International Headache Society Diagnostic Criteria in Nine Italian Headache Centers using a Computerized Structured Record. Headache, 2002, 42, 1016-1024.	3.9	13
75	Language Disturbances as a Side Effect of Prophylactic Treatment of Migraine. Headache, 2007, 48, 070623002213001-???.	3.9	13
76	Longitudinal Study on Low-Dose Aspirin versus Placebo Administration in Silent Brain Infarcts: The Silence Study. Stroke Research and Treatment, 2018, 2018, 1-9.	0.8	13
77	Dural arteriovenous fistulas and headache features: an observational study. Journal of Headache and Pain, 2020, 21, 6.	6.0	13
78	Heterozygous X-linked adrenoleukodystrophy-associated myelopathy mimicking primary progressive multiple sclerosis. Journal of Neurology, 2011, 258, 323-324.	3.6	12
79	Expression of cathepsins S and D signals a distinctive biochemical trait in CD34 ⁺ hematopoietic stem cells of relapsing–remitting multiple sclerosis patients. Multiple Sclerosis Journal, 2013, 19, 1443-1453.	3.0	12
80	Retinopathy during interferon- \hat{l}^2 treatment for multiple sclerosis: case report and review of the literature. Journal of Neurology, 2016, 263, 422-427.	3.6	12
81	High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline. Journal of the Neurological Sciences, 2017, 379, 236-240.	0.6	12
82	Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study. Neurodegenerative Disease Management, 2018, 8, 105-113.	2.2	12
83	\hat{l}^2 -N-Acetylhexosaminidase in Peripheral Blood Lymphocytes and Monocytes in the Different Forms and Stages of Multiple Sclerosis. Journal of Neurochemistry, 2002, 71, 1168-1176.	3.9	11
84	Migraine-specific quality of life questionnaire and relapse of medication overuse headache. BMC Neurology, 2015, 15, 85.	1.8	10
85	Body size and immune responses. Nutrition Research, 1996, 16, 1813-1819.	2.9	9
86	EXPRESSION OF TNF-α mRNA BY PERIPHERAL BLOOD MONONUCLEAR CELLS OF MULTIPLE SCLEROSIS PATIENTS TREATED WITH IFN-β 1A. Cytokine, 2001, 14, 294-298.	3.2	8
87	Application of ICHD 2nd edition criteria for primary headaches with the aid of a computerised, structured medical record for the specialist. Journal of Headache and Pain, 2005, 6, 205-210.	6.0	8
88	Multiple Cranial Nerve Palsies in a Patient with Internal Carotid Artery Dissection. European Neurology, 2007, 58, 125-127.	1.4	8
89	Infliximab monotherapy for neuro-Behçet's disease: A case report. Journal of the Neurological Sciences, 2014, 347, 389-390.	0.6	8
90	Application of the ICHD-II Criteria to the Diagnosis of Primary Chronic Headaches Via a Computerized Structured Record. Headache, 2007, 47, 38-44.	3.9	7

#	Article	IF	CITATIONS
91	Association Between Migraine and Headache Attributed to Stroke: A Case–Control Study. Headache, 2008, 48, 1468-1475.	3.9	7
92	Migraine with aura in the locker room: three case reports. Journal of Headache and Pain, 2012, 13, 91-93.	6.0	7
93	HDAC3 role in medication consumption in medication overuse headache patients: a pilot study. Human Genomics, 2015, 9, 30.	2.9	7
94	Long term headache duration is a factor predicting nonresponse to detoxification and advice in medication overuse headache. Journal of Headache and Pain, 2014, 15, 88.	6.0	5
95	Visual pathway involvement in multiple sclerosis: Look straight in the eyes. Multiple Sclerosis and Related Disorders, 2017, 17, 217-219.	2.0	5
96	Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes. Journal of Neurology, 2018, 265, 522-529.	3.6	5
97	Extracranial Venous Drainage Pattern in Multiple Sclerosis and Healthy Controls: Application of the 2011 Diagnostic Criteria for Chronic Cerebrospinal Venous Insufficiency. European Neurology, 2016, 76, 62-68.	1.4	4
98	Electromyographical ischemic test, clinical symptoms related to neuromuscular hyperexcitability, and intra- and extracellular Mg++ levels in headache patients. Journal of Headache and Pain, 2003, 4, 24-30.	6.0	2
99	Migraine and epilepsy: what value today?. Journal of Headache and Pain, 2015, 16, A44.	6.0	2
100	Multiple sclerosis and chronic progressive external ophthalmoplegia associated with a large scale mitochondrial DNA single deletion. Journal of Neurology, 2016, 263, 1449-1451.	3.6	2
101	Giant Basilar Apex Aneurysm Presenting as Bilateral Thalamic Compression with Neuropsychological Disorders. European Neurology, 2006, 56, 57-58.	1.4	1
102	Nerve growth factor and brain-derived neurotrophic factor: potential targets for migraine treatment?. Expert Opinion on Therapeutic Patents, 2008, 18, 705-721.	5.0	1
103	Genotype–phenotype correlation of F484L mutation in three Italian families with Thomsen myotonia. Muscle and Nerve, 2017, 55, E24-E25.	2.2	1
104	In memory of Professor Virgilio Gallai. Cephalalgia, 2004, 24, 1009-1010.	3.9	0
105	P066. Migraine with aura in the locker room: 4 case reports. Journal of Headache and Pain, 2015, 16, A169.	6.0	0
106	Medication-overuse headache: an update. Journal of Headache and Pain, 2015, 16, A46.	6.0	0
107	O064. Antiepileptic drugs in migraine and epilepsy disorders: who is at increased risk of adverse events?. Journal of Headache and Pain, 2015, 16, A69.	6.0	0
108	Epilepsy Comorbidity. Headache, 2017, , 41-63.	0.4	0

#	Article	IF	CITATIONS
109	Epilepsy, headache, and chronic pain. , 2019, , 187-205.		0
110	Teaching Images in Headache: Thrombosis of Posterior Communicating Artery Aneurysm. Headache, 2019, 59, 630-631.	3.9	0
111	Medication Overuse Headache: Causes, Consequences, and Treatment., 2012,, 351-362.		O